Cybin/Helus Nears Pivotal Phase 3 MDD Readout as Capital Concerns Linger

What happened

The primary value driver for Cybin (now Helus Pharma) is the upcoming Phase 3 APPROACH readout for HLP003 in adjunctive MDD, expected in Q4 2026, as highlighted in a recent Seeking Alpha article. The company raised additional funds in June 2026 to extend its cash runway, though quarterly burn remains elevated at ~$35 million. The stock trades at a depressed market cap of ~$413 million, with net cash of ~$135 million, reflecting the binary outcome risk. However, the bear case of a failed trial or accelerating cash burn forcing further dilutive equity issuance remains a real threat. Overall, the near-term trajectory is dominated by the APPROACH data, maintaining a highly speculative risk/reward profile.

Implication

The upcoming HLP003 Phase 3 readout in Q4 2026 is the pivotal event that will determine Cybin's future. While the company appears funded through the data, the quarterly burn of ~$35M leaves little margin for error if the trial fails or enrollment delays push data later. The stock's current price embeds significant uncertainty, and any positive data could drive a substantial re-rating, but failure would likely erase most equity value. Investors with a high risk tolerance may consider a small position ahead of the data, but conservative investors should wait for de-risking. The recent fundraise, while dilutive, provides a cleaner balance sheet but does not change the binary nature of the investment.

Thesis delta

The core thesis remains unchanged: Cybin/Helus is a binary bet on HLP003 Phase 3 data. The recent fundraise and burn rate are consistent with the Master Report's base case, and no new data has been released to shift probability weights. The WAIT stance is still appropriate until clearer enrollment and runway guidance emerge, or Phase 2 GAD data (if released) provide additional context.